ERBB2 and breast carcinoma: The overall incidence rate of HR-positive and ERBB2-positive breast cancer increased 3.6% per year from 2010 to 2016, but then decreased by 2.9% per year from 2016 to 2019, with a similar pattern observed across different age groups (Figure 4).